www.fdanews.com/articles/67607-oxxon-therapeutics-licenses-rights-to-xenova-s-disc-hsv-and-disc-gm-csf-vector-technologies
OXXON THERAPEUTICS LICENSES RIGHTS TO XENOVA'S DISC-HSV AND DISC-GM-CSF VECTOR TECHNOLOGIES
January 14, 2005
Oxxon Therapeutics has licensed exclusive worldwide rights to Xenova Group's DISC-HSV and DISC-GM-CSF vector platforms for use in developing products for certain major cancers and chronic infectious diseases. DISC-GM-CSF, used as a stand-alone product, has been tested in a number of oncology indications including a dose-ranging Phase I trial for melanoma.
Yahoo News